US targeted immunotherapies for cancer developer MAIA Biotechnology (NYSE: MAIA) yesterday announced favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced non-small cell lung cancer (NSCLC).
However, the company’s shares closed down nearly 6% at $3.28 on the news.
A Phase II clinical trial, THIO-101, is evaluating THIO sequenced with Regeneron’s (Nasdaq; REGN) immune checkpoint inhibitor (CPI) cemiplimab (trade name Libtayo in patients with advanced NSCLC who failed two or more standard-of-care therapy regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze